article thumbnail

PC Trials at State of Science: Tom LeBlanc, Kate Courtright, & Corita Grudzen

GeriPal

Kate: Yeah, some of the thoughts I’ve had in thinking about this: we did not require communication, training and education of the clinicians. We started pre-pandemic and very quickly it went to telehealth, so it was primarily telehealth. I’m just stunned even writing that! We’ve come so far as a field. Eric: Okay.

article thumbnail

Plenary Abstracts at AAHPM/HPNA: Yael Schenker, Na Ouyang, Marie Bakitas

GeriPal

And resource utilization was very low in all the groups. Eric 14:24 So it’s hard to improve resource utilization for these people where some of them didn’t sound like the sickest of people admitting them to the hospital, but all had some type of serious illness. It was not very different. It was not different.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Implementing Palliative Care in Nursing Homes: A Podcast wtih Connie Cole, Kathleen Unroe, and Cari Levy

GeriPal

Eric 17:06 Think like almost 50% of nursing home decedents utilize hospice, and that number has grown over the last two decades. Like, yeah, utilization of hospice has increased pretty well. Eric 33:25 What about telehealth? But some of these things are addressable potentially through education. Is that a black box?

article thumbnail

Telemedicine in a Post-Pandemic World: Joe Rotella, Brooke Calton, Carly Zapata

GeriPal

This DEA is taking 6-months to consider how to move forward vis a vis restrictions and requirements for telehealth in a post-pandemic world. So we’re going to be talking about telemedicine, telehealth for people with serious illness. Now is the time to act, dear listeners! This is Eric Widera. Well, what do we do now? Eric: Yeah.

article thumbnail

Senator Durbin Has Questions About FDA’s “Operational Capacity” to Oversee DTC Prescription Drug Advertising Amid Workforce Reductions – Don’t We All?

FDA Law

The Protecting Patients from Deceptive Drug Ads Online Act, co-sponsored with Senator Mike Braun (R-IN), seeks to close regulatory gaps by empowering FDA to issue Warning Letters and impose fines on social media influencers and telehealth companies that promote prescription drugs without proper disclosures of risks and side effects.